NervGen Pharma (NGENF) Stock Price, News & Analysis

Company Overview

NervGen Pharma Inc. is a clinical‐stage biotechnology company focused on developing novel therapies for injuries and diseases of the nervous system. The company’s chief development program, NVG-291, is a small‐molecule modulator of the protein tyrosine phosphatase receptor sigma (PTPσ), designed to promote nerve repair and functional recovery following central nervous system (CNS) injury. By targeting the molecular pathways that inhibit axon regeneration, NervGen aims to address high‐unmet‐need conditions such as spinal cord injury, multiple sclerosis and stroke.

NVG-291 has demonstrated proof‐of‐concept in preclinical models of CNS injury, where treatment resulted in enhanced remyelination and improved motor function. The company has advanced NVG-291 through toxicology studies and initiated a Phase 1 clinical trial in healthy volunteers to evaluate safety and pharmacokinetics. An open‐label, multi‐center Phase 1b/2 trial in patients with acute spinal cord injury is underway, with preliminary results anticipated to guide dose selection and inform future pivotal studies.

Founded in 2013 and headquartered in Richmond, British Columbia, NervGen holds an extensive intellectual property portfolio covering its PTPσ‐targeting compounds and methods of use. The company maintains operations in Canada and engagements with research centers in the United States to support its clinical programs. Under the leadership of CEO Ridgely Fisk Green, NervGen has secured strategic partnerships and funding to advance its pipeline toward regulatory milestones and potential out‐licensing or commercialization opportunities.

Key Stats

• Today's Range: $5.84 to $5.84
• 50-Day Range: $5.84 to $5.84
• 52-Week Range: $1.50 to $6.10
• Volume: N/A
• Average Volume: 134,507 shs
• Market Capitalization: $360.74 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:NGENF
• CIK: 1751912
• Web: www.nervgen.com
• Phone: (778) 731-1711
• Fax: N/A
• Employees: 7
• Year Founded: 2017

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$4.07 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -73.14%
• Return on Assets: -56.59%

Debt

• Debt-to-Equity Ratio: 0.04
• Current Ratio: 11.21
• Quick Ratio: 11.21

Sales & Book Value

• Annual Sales: $150 thousand
• Price / Sales: 2,404.91
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 61,770,000
• Free Float: N/A
• Market Cap: $360.74 million
• Optionable: Not Optionable
• Beta: N/A